Efficacy and Safety of Pharmacoinvasive Strategy Compared to Primary Percutaneous Coronary Intervention in the Management of ST-Segment Elevation Myocardial Infarction: A Prospective Country-Wide Registry

被引:10
|
作者
Zubaid, Mohammad [1 ]
Khraishah, Haitham [2 ]
Alahmad, Barrak [3 ]
Rashed, Wafa [4 ]
Ridha, Mustafa [5 ]
Alenezi, Fahad [6 ]
Aljarralah, Mohamad [7 ]
Al-Marri, Khalid [8 ]
Almutairi, Mohammad [9 ]
Althalji, Khalid [6 ]
Alfaddagh, Abdulhamied [10 ]
机构
[1] Kuwait Univ, Fac Med, Dept Med, Kuwait, Kuwait
[2] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02115 USA
[3] Harvard Univ, TH Chan Sch Publ Hlth, Environm Hlth Dept, Boston, MA 02115 USA
[4] Minist Hlth, Dept Med, Div Cardiol, Mubarak Alkabeer Hosp, Kuwait, Kuwait
[5] Minist Hlth, Dept Cardiol, Salman Aldabous Cardiac Ctr, Kuwait, Kuwait
[6] Minist Hlth, Dept Med, Div Cardiol, Alfarwaniya Hosp, Kuwait, Kuwait
[7] Minist Hlth, Dept Cardiol, Sabah Alahmad Cardiac Ctr, Kuwait, Kuwait
[8] Minist Hlth, Dept Cardiol, Chest Dis Hosp, Kuwait, Kuwait
[9] Aljahra Hosp, Dept Med, Div Cardiol, Kuwait, Kuwait
[10] Johns Hopkins Univ, Ciccarone Ctr Prevent Cardiovasc Dis, Baltimore, MD USA
来源
ANNALS OF GLOBAL HEALTH | 2020年 / 86卷 / 01期
关键词
GULF REGISTRY; TASK-FORCE; REPERFUSION; OUTCOMES; DELAYS; FIBRINOLYSIS; GUIDELINES; EXPERIENCE; TRENDS; PCI;
D O I
10.5334/aogh.2632
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background: A pharmacoinvasive reperfusion strategy is recommended for ST-elevation myocardial infarction (STEMI) patients when primary percutaneous coronary intervention (PCI) cannot be achieved in a timely fashion. This is based on a limited number of trials. The effectiveness of this strategy in the real-world is unclear. Objectives: To compare the effectiveness of pharmacoinvasive strategy versus primary PCI using a nationwide prospective registry of STEMI patients. Methods: We examined 936 STEMI patients from the reperfusion in ST-elevation myocardial infarction in Kuwait (REPERFUSE Kuwait) registry who underwent either primary PCI or pharmacoinvasive reperfusion. A composite outcome was measured based on death, congestive heart failure, reinfarction or stroke prospectively ascertained during hospital stay and up to one-year follow-up. The association between reperfusion strategy and the composite outcome was assessed using multivariate regression and Poisson proportional hazard model. Results: Compared to the pharmacoinvasive group, those undergoing primary PCI had higher Killip class on presentation and required more blood transfusions during hospitalization. There was no significant difference between primary PCI and pharmacoinvasive strategy with regards to the incidence of the composite outcome during the in-hospital period (RR = 1.0; 95% CI 0.98-1.02; p = 0.96) after adjustment for possible confounders. Over one-year follow-up, the survival of the two groups was not different (p = 0.66). The incidence of major bleeding was similar in both groups. Conclusion: STEMI patients treated with a pharmacoinvasive strategy have comparable outcomes to those treated with primary PCI with no increased risk of major bleeding. These real-world data support the use of a pharmacoinvasive strategy when primary PCI cannot be achieved in a timely fashion.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Outcomes in ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention or pharmacoinvasive strategy in a Latin American country
    Chacon-Diaz, Manuel
    Custodio-Sanchez, Piero
    Rojas de la Cuba, Paol
    Yabar-Galindo, German
    Rodriguez-Olivares, Rene
    Miranda-Noe, David
    Lopez-Rojas, Luis Marcos
    Hernandez-Vasquez, Akram
    BMC CARDIOVASCULAR DISORDERS, 2022, 22 (01)
  • [2] Safety and Efficacy of a Pharmacoinvasive Strategy in ST-Segment Elevation Myocardial Infarction A Patient Population Study Comparing a Pharmacoinvasive Strategy With a Primary Percutaneous Coronary Intervention Strategy Within a Regional System
    Rashid, Mohammed K.
    Guron, Nita
    Bernick, Jordan
    Wells, George A.
    Blondeau, Melissa
    Chong, Aun-Yeong
    Dick, Alexander
    Froeschl, Michael P. V.
    Glover, Chris A.
    Hibbert, Benjamin
    Labinaz, Marino
    Marquis, Jean-Francois
    Osborne, Christina
    So, Derek Y.
    Le May, Michel R.
    JACC-CARDIOVASCULAR INTERVENTIONS, 2016, 9 (19) : 2014 - 2020
  • [3] Outcomes in ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention or pharmacoinvasive strategy in a Latin American country
    Manuel Chacón-Diaz
    Piero Custodio-Sánchez
    Paol Rojas De la Cuba
    Germán Yábar-Galindo
    René Rodríguez-Olivares
    David Miranda-Noé
    Luis Marcos López-Rojas
    Akram Hernández-Vásquez
    BMC Cardiovascular Disorders, 22
  • [4] Pharmacoinvasive Strategy Versus Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction in Patients ≥70 Years of Age
    Auffret, Vincent
    Laurin, Clement
    Leurent, Guillaume
    Didier, Romain
    Filippi, Emmanuelle
    Hacot, Jean-Philippe
    Zabalawi, Amer
    Rouault, Gilles
    Saouli, Djamel
    Druelles, Philippe
    Coudert, Isabelle
    Boulanger, Bertrand
    Bot, Emilie
    Treuil, Josiane
    Bedossa, Marc
    Boulmier, Dominique
    Loirat, Aurelie
    Sharobeem, Sam
    Le Guellec, Marielle
    Gilard, Martine
    Le Breton, Herve
    AMERICAN JOURNAL OF CARDIOLOGY, 2020, 125 (01) : 1 - 10
  • [5] Pharmacoinvasive Strategy Versus Primary Percutaneous Coronary Intervention in Patients With ST-Segment-Elevation Myocardial Infarction: A Propensity Score-Matched Analysis
    Sim, Doo Sun
    Jeong, Myung Ho
    Ahn, Youngkeun
    Kim, Young Jo
    Chae, Shung Chull
    Hong, Taek Jong
    Seong, In Whan
    Chae, Jei Keon
    Kim, Chong Jin
    Cho, Myeong Chan
    Rha, Seung-Woon
    Bae, Jang Ho
    Seung, Ki Bae
    Park, Seung Jung
    CIRCULATION-CARDIOVASCULAR INTERVENTIONS, 2016, 9 (09)
  • [6] Primary Percutaneous Coronary Intervention as a National Reperfusion Strategy in Patients With ST-Segment Elevation Myocardial Infarction
    Terkelsen, Christian J.
    Jensen, Lisette O.
    Tilsted, Hans H.
    Thaysen, Per
    Ravkilde, Jan
    Johnsen, Soren P.
    Trautner, Sven
    Andersen, Henning R.
    Thuesen, Leif
    Lassen, Jens F.
    CIRCULATION-CARDIOVASCULAR INTERVENTIONS, 2011, 4 (06) : 570 - 576
  • [7] The Efficacy and Safety of Pharmacoinvasive Therapy with Prourokinase for Acute ST-Segment Elevation Myocardial Infarction Patients with Expected Long Percutaneous Coronary Intervention-Related Delay
    Han, Ya-Ling
    Liu, Jian-Ning
    Jing, Quan-Min
    Ma, Ying-Yan
    Jiang, Tie-Min
    Pu, Kui
    Zhao, Rui-Ping
    Zhao, Xin
    Liu, Hai-Wei
    Xu, Kai
    Wang, Geng
    Wang, Bin
    Sun, Rui-Hua
    Wang, Jie
    CARDIOVASCULAR THERAPEUTICS, 2013, 31 (05) : 285 - 290
  • [8] Efficacy and Safety of Abbreviated Eptifibatide Treatment in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
    Fischer, Florian
    Buxy, Samriddhi
    Kurz, David J.
    Eberli, Franz R.
    Senn, Oliver
    Zbinden, Rainer
    Held, Ulrike
    Meyer, Matthias R.
    AMERICAN JOURNAL OF CARDIOLOGY, 2021, 139 : 15 - 21
  • [9] Recurrent Myocardial Infarction After Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction
    Kikkert, Wouter J.
    Hoebers, Loes P.
    Damman, Peter
    Lieve, Krystien V. V.
    Claessen, Bimmer E. P. M.
    Vis, Marije M.
    Baan, Jan, Jr.
    Koch, Karel T.
    de Winter, Robbert J.
    Piek, Jan J.
    Tijssen, Jan G. P.
    Henriques, Jose P. S.
    AMERICAN JOURNAL OF CARDIOLOGY, 2014, 113 (02) : 229 - 235
  • [10] Efficacy and Safety of Early Intravenous Landiolol on Myocardial Salvage in Patients with ST-segment Elevation Myocardial Infarction before Primary Percutaneous Coronary Intervention: A Randomized Study
    Miyamoto, Masakazu
    Osawa, Kazuhiro
    Miyoshi, Toru
    Mori, Atsushi
    Yoshikawa, Masaki
    Oka, Takefumi
    Ichikawa, Keishi
    Nakamura, Kazufumi
    Ito, Hiroshi
    ACTA MEDICA OKAYAMA, 2021, 75 (03) : 289 - 297